Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Efficacy and Safety of Palonosetron in Treatment of Postoperative Nausea and Vomiting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years and older, younger than 70 years old~* American society of Anesthesiologists physical status classification I to III~* those who undergo laparoscopic gynecologic, abdominal or other surgery under general anesthesia~* surgery for which anesthesia is expected to last at least 30 minutes~* if a subject has or may develop prolongation of cardiac conduction intervals, particularly corrected QT interval, he/she may be enrolled at the discretion of the investigator.~Exclusion Criteria:~* known hypersensitivity/ contraindication to 5-hydroxytryptamine antagonists or study drug excipient~* inability to understand or cooperate with the study procedures as determined by the investigator~* women who are pregnant, nursing or planning to become pregnant, are not using effective birth control, or that have had a positive serum pregnancy test within 7 days prior to surgery day 1.~* has received any investigational drug within 30 days before study entry~* having taken any drug with potential antiemetic efficacy within 24 hour prior to anesthetic procedures.~* any vomiting, retching, or nausea in the 24 hours preceding the administration of anesthesia~* known or suspected current history of alcohol abuse or drug abuse.~* any condition, which in the opinion of the investigator would make the subject ineligible for participation in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Palonsetron (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).